Key clinical point: Lemborexant effectively treated both sleep onset and sleep maintenance variables in men and women with insomnia.
Major finding: In both sexes, subject-reported sleep onset latency was significantly reduced versus that of placebo for lemborexant 5 mg and lemborexant 10 mg during the first 7 days and end of month 1 (P less than .05 for all comparisons).
Study details: A pooled analysis of data from 1,693 subjects enrolled in SUNRISE-1 and SUNRISE-2.
Disclosures: The research was supported by Eisai. Dr. Moline is an employee of the company.
Moline M et al. Sleep 2019, Abstract 0368.